Other substances

mRNA-RBD

A candidate COVID-19 mRNA vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

mRNA-RBD is a nucleoside-modified mRNA vaccine formulated in lipid nanoparticles. It uses SARS-CoV-2 Spike RBD as the immunogen (Huang et al., 2021).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2 RNA Animal model In vitro Mixed substance	cryo-EM; Huh7 cells (pseudovirus neutralization assay); C57BL/6 mice; hACE2-expressing BALB/c mice; SARS-CoV-2 strain hCoV-19/Wuhan/IVDC-HB-01/2019	12.12	A single dose of the experimental vaccine elicited potent neutralizing antibody and CD4+ and CD8+ T-cell responses in a murine model. hACE2-expressing mice were almost completely protected from SARS-CoV-2 infection (weight-loss, lung viral loads, and lung pathology assessment) and the neutralizing antibody response was long-lasting. After a second immunization the NT90 titres reached 2000 (170 after a single immunization).	Feb/03/2021

AI-suggested references

Link	Publication date
Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants.	May/20/2022
Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate	May/30/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT05272605	Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults	Not yet recruiting	Phase 1	Mar/15/2022	Dec/31/2022
Alternative id - UoM-SARS-CoV-2-01 Interventions - Biological: Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)\|Biological: SARS-CoV-2 beta variant RBD mRNA vaccine\|Other: Normal Saline Study type - Interventional Study results - No Results Available Locations - Vaccine and Immunisation Research Group, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia\|Royal Melbourne Hospital, Victorian Infectious Diseases Service (VIDS), Melbourne, Victoria, Australia Study designs - Allocation: Randomized\|Intervention Model: Sequential Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 114 Age - 18 Years to 70 Years (Adult, Older Adult) Outcome measures - Serious adverse events (SAEs), medically attended adverse events (MAAEs) and any adverse events (AEs) leading to study withdrawal at any time during the study.\|SAEs post vaccination.\|Solicited local and systemic reactogenicity AEs post vaccination.\|Unsolicited AEs post vaccination.\|Percentage of participants who achieve a boost response post vaccination.\|MAAEs from Day 1 to 6 months after vaccination.\|The number of participants that develop an antibody response at least 4 times higher than baseline antibody titers.\|Number of participants that mount a T cell response for SARS-CoV-2 RBD-derived peptide antigens.\|Number of participants that mount a T cell response that leads to type-1 cytokines (such as Interferon-gamma) versus type-2 cytokines (such as Interleukin 4, 5 and 13).\|The ratio of T cell derived type 1 versus type 2 cytokines in participants that mount a T cell response.

Export (.csv)